Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Seres Therapeutics, Inc.'s quarterly P/E stands at 5.1x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.50 | 5.14 | — | 0.93 | — | — | — | — | — | — | 3.34 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | 120.20 | — | — | — | — | — | — | 706.90 | — | 1.23 | — | 179.81 |
| — | — | — | — | — | — | — | — | +293.1% | — | -98.1% | — | +578.5% | |
| P/B Ratio | 5.37 | 3.86 | 2.95 | 2.42 | 10.43 | 6.04 | — | — | — | — | 27.50 | — | 65.03 |
| — | -36.0% | — | — | — | — | — | — | — | — | +100.4% | — | +1017.3% | |
| P/FCF | — | 19.20 | — | 1.13 | — | — | — | — | — | — | 2.40 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | 2.96 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 6.29 | — | 1.17 | — | — | — | — | — | — | 3.06 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Seres Therapeutics, Inc.'s operating margin was -6403.7% in Q3 2025.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | -3704.0% | — | — | — | — | — | — | 100.0% | — | 63.0% | 8523.2% | -4640.5% |
| — | — | — | — | — | — | — | — | +102.2% | — | +101.8% | +433.5% | -1034.7% | |
| Operating Margin | — | -6403.7% | — | — | — | — | — | — | -61759.4% | — | 39.2% | 13518.8% | -7005.8% |
| — | — | — | — | — | — | — | — | -781.5% | — | +100.8% | +462.0% | -923.4% | |
| Net Margin | — | 2337.3% | — | — | — | — | — | — | -64450.0% | — | 36.8% | 13634.9% | -7056.0% |
| — | — | — | — | — | — | — | — | -813.4% | — | +100.7% | +459.5% | -919.0% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1.0% | 21.4% | -47.6% | 101.7% | -82.9% | 371.2% | — | — | — | -1277.6% | 205.9% | — | -175.6% |
| — | -94.2% | — | — | — | +129.0% | — | — | — | -865.0% | +265.4% | — | -439.4% | |
| ROA | 0.1% | 5.7% | -12.9% | 21.5% | -9.8% | 35.5% | -9.9% | -11.5% | -11.4% | -12.4% | 13.8% | -23.0% | -20.8% |
| — | -83.9% | -30.0% | +287.5% | +13.6% | +386.9% | -172.1% | +50.1% | +45.5% | +39.7% | +163.0% | -37.0% | -56.4% | |
| ROIC | -180.9% | -21.6% | -23.9% | -26.2% | -34.5% | -41.7% | -44.4% | -74.6% | -111.4% | -201.1% | 285.6% | -348.9% | — |
| — | +48.2% | +46.2% | +64.9% | +69.0% | +79.3% | -115.5% | +78.6% | — | — | — | +74.5% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 104.2% YoY to 2.30x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 6.65 | 1.95 | 2.65 | 1.77 | 6.65 | 3.91 | — | — | — | — | 9.42 | — | 15.08 |
| — | -50.1% | — | — | — | — | — | — | — | — | +181.2% | — | +3929.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 4.17 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.94 | 2.30 | 1.57 | 2.11 | 0.94 | 1.12 | 1.38 | 1.68 | 1.78 | 2.71 | 3.23 | 1.82 | 2.28 |
| — | +104.2% | +14.1% | +25.8% | -47.2% | -58.4% | -57.3% | -7.8% | -21.9% | -10.5% | +37.0% | -43.1% | -38.4% | |
| Quick Ratio | 0.94 | 2.30 | 1.57 | 2.11 | 0.94 | 1.12 | 0.89 | 1.25 | 1.48 | 2.47 | 3.16 | 1.82 | 2.28 |
| — | +104.2% | +77.0% | +68.6% | -36.5% | -54.5% | -71.8% | -31.2% | -35.1% | -18.3% | +34.1% | -43.1% | -38.4% | |
| Interest Coverage | — | — | — | — | — | — | -8.38 | -7.39 | -9.81 | -11.11 | 15.54 | -36.23 | -36.33 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonSeres Therapeutics, Inc.'s current P/E is -0.5x. The average P/E over the last 2 quarters is 3.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Seres Therapeutics, Inc.'s business trajectory between earnings reports.